Abstract
Background. Chronic kidney disease (CKD) is a common complication of solid organ transplantation with a substantial risk of progression to end-stage renal disease (ESRD). The impact of dialysis modality on morbidity and mortality is unknown in these patients. The aim of the present analysis was to describe our experience with home dialysis [peritoneal dialysis (PD) and home haemodialysis (HHD)] to assess the feasibility of this modality in patients who developed ESRD after nonrenal solid organ transplant (NRSOT). Methods. A retrospective observational cohort study with consecutive patients initiated on home dialysis after NRSOT from 2000 to 2009 was conducted. We collected data on patient demographics, laboratory parameters and blood pressure as well as clinical adverse events using our electronic clinical database.
Results. Between 2000 and 2009, 25 patients [median age, 56 years; interquartile range (IQR), 43-65 years] initiated home dialysis. Ten patients started HHD and 15 patients initiated PD. The types of NRSOT were liver (n=11), heart (n=8), lung (n=5) and heart-lung (n=1). The median vintage of NRSOTat the time of dialysis initiation was 8.7 years (IQR, 6.3-11.4 years). The median home dialysis follow-up was 24 months (IQR, 15-53 months). The median values of blood pressure, phosphate, calcium, parathyroid hormone and haemoglobin were within the K/DOQI targets. The hospitalization and infection rates were 1 episode every 22 and 29 patient-months, respectively. Three patients switched to in-centre conventional HD during follow-up and eight patients died. Conclusions. Home dialysis (PD and HHD) is a feasible and sustainable modality for patients with ESRD after NRSOT. Home dialysis offers several potential benefits,
Introduction
Nonrenal solid organ transplantation (NRSOT) is often complicated by the development of chronic kidney disease (CKD) [1-4] with calcineurin inhibitor (CNI) nephrotoxicity being primarily responsible [5, 6] . After reaching CKD Stage IV, these patients have a 29% risk of requiring renal replacement therapy and they constitute 3-5% of the prevalent chronic HD population in the United States [7] .
The impact of the choice of the dialysis modality in NRSOT patient is unknown. Renal registry data suggest that peritoneal dialysis (PD) is underused in the setting of NRSOT [8] [9] [10] , potentially because of perceptions of infectious complications and poor technique survival. Heterogeneous results favouring both PD [11] and HD [12] provide no uniform recommendation for this vulnerable patient population. Home haemodialysis (HHD) is a renal replacement modality that has received renewed interest. However, no study has evaluated the possibility of this modality in patients who develop end-stage renal disease (ESRD) after NRSOT.
The aim of the present study was to describe our experience in performing home dialysis (PD and HHD) in patients who developed ESRD after NRSOT to assess the feasibility of both modalities.
Materials and methods

Design and definition
This is a retrospective observational cohort study. Institutional research ethics board approval was obtained. Information obtained was validated with electronic and paper charts. Subjects included all consecutive incident ESRD patients initiating home dialysis therapy (PD and HHD) at the Toronto General Hospital, University Health Network, from 1 January 2000 to 31 December 2009. Demographic variables included age, gender, aetiology of ESRD and comorbid conditions. Other collected data consisted of the type of NRSOT, primary disease necessitating NRSOT, vintage of NRSOT at the start of home dialysis, home dialysis follow-up and disposition (transfer to in-centre HD, kidney transplant or death) until 31 December 2009. Estimated GFR at the time of home dialysis initiation using the four-variable MDRD formula [13] , blood pressure and standard laboratory parameters (calcium, phosphorus, parathyroid hormone, haemoglobin and albumin) were collected at time of home dialysis initiation and every 6 months until termination of home dialysis. All data in HHD patients were collected prior to their dialysis session. Data from PD patients were obtained from their routine clinic blood work. We assessed clinical adverse events including infection, hospitalization, development of cancer and death.
Dialysis prescription
Our HHD patients were dialysed 4-7 days a week for 5-8 h overnight using a conventional dialysis platform and a high-flux biocompatible dialyser. A dialysate flow rate of 200-350 mL/min and a blood flow rate of 250-300 mL/min were used. Unfractionated heparin was used during treatments. Our PD patients were on either continuous ambulatory PD or continuous cycling PD. The prescriptions were adjusted according to their treating physician, fluid status and laboratory results.
Statistical analysis
Continuous variables were expressed as median and interquartile range (IQR). Categorical variables were expressed as number. Continuous data were compared using the Mann-Whitney test, while dichotomous data were compared by Pearson's chi-square analysis. All P-values were twotailed, and values <0.05 were considered significant. All analyses were performed using SPSS-16 (SPSS, Chicago, IL).
Results
During the study period, 25 patients initiated home dialysis (15 on PD and 10 on HHD) after NRSOT at the Toronto General Hospital. Baseline characteristics are summarized in Table 1 . The median age of our cohort was 54 years (IQR, 43-65 years). Sixteen patients were male. The types of NRSOT were liver (11 patients), heart (8 patients), lung (5 patients) and heart-lung (1 patient). The median duration of NRSOT at the time of home dialysis initiation was 8.7 years (IQR, 6.3-11.4 years). The most frequent cause of ESRD was CNI nephrotoxicity. The estimated GFR at the time of initiation of home dialysis ranged from 5 to 15 mL/min. Six patients had another renal replacement modality (five conventional HD and one renal transplant) before initiating home dialysis. The median home dialysis follow-up was 24 months (IQR, 15-53 months). Six patients had a kidney transplant during follow-up.
Laboratory parameters and blood pressure after home dialysis initiation are outlined in Table 2 . All median values of laboratory parameters and blood pressure were within the K/DOQI targets [14] [15] [16] . There was no statistically significant difference in laboratory values or blood pressure control between PD and HHD patients.
The clinical adverse events are summarized in Table 3 . A total of 18 peritonitis and 3 line sepsis were documented during the follow-up. The peritonitis rate was 1 for every 29 patient-months among the 15 PD patients. This rate was 1 for every 32 patient-months among the liver transplant recipients on PD. Three patients were converted to incentre HD: one HHD patient after 12 months because of hepatic encephalopathy, one PD patient after 26 months because of PD catheter removal for Pseudomonas peritonitis and another PD patient decided to change modality after one episode of peritonitis. Eight patients (three in HHD and five in PD) expired during follow-up. The causes of death were cancer (n=3), myocardial infarction (n=1), fatal arrhythmia following a myocardial infarction (n=1), ischaemic bowel (n=1) and septic shock following PD peritonitis (n=1) and pneumonia (n=1).
Discussion
In the present study, we describe our experience with home dialysis (PD and HHD) for patients who developed ESRD after NRSOT. This study is the first to assess both PD and HHD as potential renal replacement modalities after NRSOT. To our knowledge, this study provides the longest follow-up (median, 24 months) of home dialysis in NRSOT recipients. Our results illustrate that (i) home dialysis is a feasible and sustainable modality in patients who develop ESRD after NRSOT and (ii) home dialysis might provide specific benefits for this particular patient population.
The peritonitis rate in our cohort of transplant patients (1 episode per 29 patient-months) was higher compared to the rate of our programme as a whole (1 episode per 39 patient-months). This may be a simple variation based on a small number of patients included in the study or may be explained in part by the fact that PD patients on immunosuppressive therapy are at greater risk for peritonitis [17] . However, the peritonitis rate in our cohort of patients was lower compared to the published literature in heart and heart-lung transplant recipients on PD (1 episode per 15 patient-months) [18] . To date, no comparable data are available in the HHD literature.
The hospitalization rate in our cohort of patients (1 episode per 22 patient-months) was higher compared to our dialysis population overall (1 episode per 30 patientmonths; unpublished data). In the majority of cases, the reasons for hospitalization were not directly related to complications of dialysis (Table 3) . It is reasonable to postulate that NRSOT patients are more likely to be hospitalized because of their comorbidities. The trend toward a lower hospitalization rate among HHD patients may be explained by selection bias since our HHD patients tend to be younger with less comorbid burden [19] .
Potential advantages of PD in NRSOT were recently summarized [20] . They include reduction of the risk for viral transmission of hepatitis to non-infected dialysis patients [21, 22] , optimization of haemodynamic stability during dialysis in the context of slow continuous ultrafiltration [23] , avoidance of bacteraemia related to dialysis catheter and the potential preservation of residual renal function [24] . Nocturnal HHD is also associated with several potential benefits including improved blood pressure control [25] , regression of left ventricular hypertrophy and improved left ventricular ejection fraction [26, 27] , optimization of phosphate control [28] and improved survival compared to conventional HD [29] . Our home dialysis cohort had blood pressure and laboratory parameters within the K/DOQI targets for the first 2 years of follow-up [14] [15] [16] . These advantages of home dialysis, both PD and HHD, are crucial in the management of NRSOT patients who might benefit from (i) optimized haemodynamic stability and (ii) improved metabolic control which is essential in the context of CNI's metabolic side effects.
It is also worth noting that eight liver transplant patients successfully used PD as their dialysis modality. Furthermore, the rate of peritonitis was not higher among liver transplant recipients on PD. This extends the previous observation that PD should not be withheld from liver transplant patients [30, 31] .
Based on our results, home dialysis should be considered as a first-line therapy for NRSOT patients developing ESRD. Patients should be educated about home dialysis to provide the renal replacement therapy best suited to their lifestyle and medical conditions [32, 33] . The promotion of home dialysis in this vulnerable population may help to All values represented as number unless otherwise specified. No statistically significant differences were found when comparing PD and HHD patients. a Diarrhoea (n=1), hepatic encephalopathy (n=1) and noncardiac chest pain (n=1). b Haemoperitoneum (n=1), parathyroidectomy (n=1), diarrhoea (n=1), failure to cope (n=3), seizure (n=2), upper gastrointestinal bleeding (n=1), gout attack (n=1), encephalopathy (n=2) and warfarin overdose (n=1).
preserve their quality of life, which should be examined in future studies. Our study is limited by its retrospective nature. We were unable to compare our cohort of patients on home dialysis with in-centre conventional HD patients because of selection bias. Furthermore, due to our small sample size, we might not be able to identify modest differences between PD and HHD patients. Finally, the outcomes of our cohort of patients could be in part explained by a selection bias since healthier and younger patients might be more prone to choose home dialysis.
Conclusion
In conclusion, home dialysis is a feasible and sustainable alternative to in-centre conventional HD to treat ESRD in NRSOT. However, larger multicentre studies are needed to compare home dialysis versus in-centre HD among NRSOT patients. Studies focusing on home dialysis outcomes and selection criteria merit further investigation.
